Taysha Gene Therapies, Inc. TSHA
We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, we aim to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. Our management team has proven experience in gene therapy development and commercialization. We leverage this experience, our manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M | — | — | — |
| R&D | $86.4M | $66.0M | $56.8M | $91.2M | $131.9M | $31.9M | — |
| SG&A | $33.9M | $29.0M | $30.0M | $37.4M | $41.3M | $11.1M | — |
| Total operating expenses | $120.3M | $99.8M | $87.9M | $164.9M | $173.3M | $43.0M | — |
| Operating income | -$110.5M | -$91.5M | -$72.4M | -$162.4M | -$173.3M | -$43.0M | — |
| Interest expense | $63.0K | $102.0K | $5.0M | $3.8M | $1.4M | $28.0K | — |
| Pre-tax income | -$109.0M | -$89.3M | -$111.6M | -$166.0M | — | -$60.0M | — |
| Income tax | $0 | $0 | $0 | $0 | — | $0 | — |
| Net income | -$109.0M | -$89.3M | -$111.6M | -$166.0M | -$174.5M | -$60.0M | — |
| EPS, basic | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | — | — |
| EPS, diluted | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 | — |
| Shares, diluted (wtd. avg.) | 319.7M | 250.1M | 116.1M | 44.0M | 37.7M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $319.8M | $139.0M | $143.9M | $87.9M | $149.1M | $251.3M | — |
| Total current assets | $324.6M | $142.1M | $149.9M | $96.4M | $159.6M | $257.9M | $15.0K |
| Property, plant and equipment | $6.7M | $7.5M | $10.8M | $15.0M | $50.6M | $287.0K | — |
| Total assets | $343.3M | $160.4M | $172.7M | $126.3M | $214.0M | $258.9M | $15.0K |
| Accounts payable | $6.3M | $3.6M | $6.4M | $10.9M | $21.8M | $2.0M | — |
| Total current liabilities | $26.6M | $26.2M | $36.8M | $62.8M | $51.7M | $7.1M | $150.0K |
| Long-term debt | $50.1M | $43.9M | $40.5M | $38.0M | $37.2M | — | — |
| Total liabilities | $96.4M | $88.8M | $97.8M | $125.3M | $118.6M | $7.6M | $150.0K |
| Retained earnings | -$711.3M | -$602.3M | -$513.0M | -$401.4M | -$235.6M | -$61.1M | -$1.1M |
| Total equity | $246.9M | $71.5M | $74.9M | $949.0K | $95.4M | $251.3M | -$135.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$93.1M | -$81.2M | -$73.0M | -$88.4M | -$117.0M | -$30.7M | — |
| Depreciation and amortisation | $1.1M | $1.2M | $1.4M | $1.2M | $492.0K | $9.0K | — |
| Stock-based compensation | $13.3M | $13.1M | $7.9M | $18.0M | $18.2M | $3.4M | — |
| Capital expenditure | $738.0K | $374.0K | $3.9M | $20.6M | $15.3M | $82.0K | — |
| Investing cash flow | -$604.0K | -$363.0K | -$7.4M | -$24.9M | -$21.6M | -$9.1M | — |
| Financing cash flow | $274.6M | $76.7M | $136.4M | $52.1M | $39.1M | $291.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-168525.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.5M | $15.5M | $8.3M | $9.8M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$60.0M | -$174.5M | -$166.0M | -$111.6M | -$89.3M | -$109.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Results announced Item 2.02
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |